Clinical trial success for new cancer drug for patients with same faulty gene as Angelina Jolie
A new cancer drug for patients with the same faulty gene as actress Angelina Jolie has shown ‘impressive responses’ in a clinical trial, researchers have said.
The potential drug, called BMN 673, targets DNA repair in cancer cells and is designed to attack tumours that have been left vulnerable by genetic mutations.
BRCA genes were brought into the public consciousness last month after Jolie, 37, revealed she underwent a double mastectomy when doctors told her that her faulty gene – BRCA1 – meant she had an 87 per cent risk of developing breast cancer and a 50 per cent risk of ovarian cancer.
Faulty gene: Angelina Jolie arriving for the world premiere of World War Z, at the Empire Leicester Square, London. Last month she revealed she underwent a double mastectomy
Scientists studying BMN 673 found the drug was ‘well tolerated’ by patients and showed ‘excellent anti-tumour activity’, the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust said.
The results of the trial – which was funded by US firm BioMarin Pharmaceutical and involved the University of Newcastle and several American institutions – were presented at the American Society of Clinical Oncology (Asco) meeting in Chicago yesterday.
EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision (opinion)
Angelina Jolie’s announcement of undergoing a double mastectomy (surgically removing both breasts) even though she had no breast cancer is not the innocent, spontaneous, “heroic choice” that has been portrayed in the mainstream media. Natural News has learned it all coincides with a well-timed for-profit corporate P.R. campaign that has been planned for months and just happens to coincide with the upcoming U.S. Supreme Court decision on the viability of the BRCA1 patent.
This is the investigation the mainstream media refuses to touch. Here, I explain the corporate financial ties, investors, mergers, human gene patents, lawsuits, medical fear mongering and the trillions of dollars that are at stake here. If you pull back the curtain on this one, you find far more than an innocent looking woman exercising a “choice.” This is about protecting trillions in profits through the deployment of carefully-crafted public relations campaigns designed to manipulate the public opinion of women.
The signs were all there from the beginning of the scheme: Angelina Jolie’s highly polished and obviously corporate-written op-ed piece at the New York Times, the carefully-crafted talking points invoking “choice” as a politically-charged keyword, and the obvious coaching of even her husband Brad Pitt who carefully describes the entire experience using words like “stronger” and “pride” and “family.”
But the smoking gun is the fact that Angelina Jolie’s seemingly spontaneous announcement magically appeared on the cover of People Magazine this week — a magazine that is usually finalized for publication three weeks before it appears on newsstands. That cover, not surprisingly, uses the same language found in the NYT op-ed piece: “HER BRAVE CHOICE” and “This was the right thing to do.” The flowery, pro-choice language is not a coincidence.
What this proves is that Angelina’s Jolie’s announcement was a well-planned corporate P.R. campaign with carefully-crafted messages designed to influence public opinion. But what could Jolie be seeking to influence?
…how about trillions of dollars in corporate profits?